
This Week in Virology TWiV 1266: Clinical update with Dr. Daniel Griffin
Nov 1, 2025
Dr. Daniel Griffin, an infectious disease clinician, provides an insightful clinical update on various viral infections. He discusses how mRNA vaccines may enhance cancer therapies and reveals new meta-analysis findings on COVID-19, RSV, and influenza vaccines. Dr. Griffin also highlights rising measles cases and H5N1 outbreaks in poultry. He addresses long COVID treatments, vaccine effectiveness against severe illness, and the limitations of wastewater surveillance for RSV, all while encouraging public health awareness.
AI Snips
Chapters
Transcript
Episode notes
Why Wastewater Misses RSV
- Wastewater surveillance poorly captures RSV because the main affected group (infants) wear diapers, diverting viral material from sewage.
- ER visit tracking by state gives earlier and more reliable RSV signal.
RSV mRNA Revaccination Restores Antibodies
- Revaccination with Moderna mRNA-1345 at 12 months is immunogenic and well tolerated in adults 50+ and restores antibody titers.
- Expect mild-to-moderate reactions and no new safety concerns in the studied cohort.
England's RSV Program Strongly Protective
- England's bivalent RSV pre-F program achieved very high vaccine effectiveness (72–89%) against hospital admissions and severe RSV outcomes in older adults.
- Effectiveness remained robust across exacerbations of chronic lung, heart disease, and immunosuppression groups.

